Video

Dr. Broghammer on patient selection for treatment with intracavernosal injections

Author(s):

Urology Times staff
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Joshua A. Broghammer, MD, discusses the ideal patient population for treatment with intracavernosal injections for erectile dysfunction. Broghammer is an associate professor of Urology at the University of Kansas Medical Center.

      Related Videos
      Experts consider efficacy of fertility restoration vs sperm cryopreservation
      Experts consider efficacy of fertility restoration vs sperm cryopreservation
      Matthew Mutter, MD, shares data on Separo vessel sealing system for vasectomy
      Matthew Mutter, MD, shares data on Separo vessel sealing system for vasectomy
      Fertility restoration may offer benefits in cost, efficacy vs sperm cryopreservation
      Fertility restoration may offer benefits in cost, efficacy vs sperm cryopreservation
      Investigators discuss cost-effectiveness study of cryopreservation vs vasectomy reversal
      Investigators discuss cost-effectiveness study of cryopreservation vs vasectomy reversal
      Justin Dubin, MD, answers a question during a video interview
      Justin Dubin, MD, on potential health effects of SARMs and anabolic steroids
      Man talking with a doctor | Image Credit: © RFBSIP - stock.adobe.com
      Study identifies trends in testosterone use in young adult men
      Kristy L. Mardis, NP, on APP development initiatives in sexual medicine
      Kristy L. Mardis, NP, on APP development initiatives in sexual medicine
      Dr. Nam on potential future research on vasectomy in the post-Dobbs era
      Dr. Nam on potential future research on vasectomy in the post-Dobbs era
      Dr. Nam on the increased interest in vasectomy amidst urologist shortages
      Dr. Nam on the increased interest in vasectomy amidst urologist shortages
      Dr. Rust recaps the SMSNA Men’s Health Fellowship Bootcamp
      Dr. Rust recaps the SMSNA Men’s Health Fellowship Bootcamp
      Related Content
      Long-term data point to durable efficacy of Optilume for urethral strictures
      May 13th 2025

      Long-term data point to durable efficacy of Optilume for urethral strictures

      Hannah Clarke
      The freedom from re-intervention rate was 71%.
      Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
      May 17th 2025

      Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

      Amy M. Pearlman, MD Alex Tatem, MD
      Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
      Du Geon Moon, MD, PhD | Credit: Korea University College of Medicine
      April 27th 2025

      Sildenafil/Clomipramine Combo Boosts Outcomes in Premature Ejaculation

      Patrick Campbell
      A phase 3 trial reveals a combination therapy for premature ejaculation significantly enhances treatment outcomes.
      Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
      May 4th 2025

      Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

      Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
      Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
      Label change for testosterone: Implications for urologists, prescribers, and patients
      April 9th 2025

      Label change for testosterone: Implications for urologists, prescribers, and patients

      Hannah Clarke
      In February 2025, the FDA recommended a removal of the black box warning related to an increased risk of adverse cardiovascular outcomes for all testosterone products. This recommendation has important implications for urologists and the patients they treat.
      Study links poor semen quality with shorter life span
      March 5th 2025

      Study links poor semen quality with shorter life span

      Hannah Clarke
      The average life expectancy was 80.3 years among men with a total motile sperm count over 120 million, compared with 77.6 years among men with a total motile sperm count ranging from >0 to 5 million.
      © 2025 MJH Life Sciences

      All rights reserved.